Overview
Trima Accel Automated Blood Collection System Reveos Automated Blood Processing System Welders & Sealers Reliable, sterile connections using cost-effective tubing welders and sealers Whole Blood Bag Systems Whole blood collection, component processing and storage Mirasol Pathogen Reduction Technology (PRT) System
See all
TOMEs Terumo Operational Medical Equipment Software Trima KPI Dashboard Data visualization and KPIs Cadence Data Collection System Veda Solutions Service | Analytics | Consulting Vista Information System
See all
Overview
Spectra Optia Apheresis System Red Blood Cell Exchange Therapeutic Apheresis Red Blood Cell Exchange Cell Collections Comprehensive cell collection solutions Vascular Access Your resource for optimizing vascular access for each and every patient Sickle Cell Disease Transfusion Therapy for Sickle Cell Disease
See all
Cell Collection Services Spectra Optia Cell Collection Services Veda Solutions Service | Analytics | Consulting
See all
Overview
Quantum Flex Cell Expansion System FINIA Fill and Finish System Welders & Sealers Reliable, sterile connections using cost-effective tubing welders and sealers
See all
Cell Collection Services Comprehensive cell collection solutions Veda Solutions Service | Analytics | Consulting
See all
Overview
Welders & Sealers Reliable, sterile connections using cost-effective tubing welders and sealers Accessories for Blood Centers Collection, processing and storage needs.
See all
Veda Solutions Service | Analytics | Consulting Contract Manufacturing Innovation and quality in contract manufacturing
See all
Overview
Product Security Product Certificates Safety Data Sheets Technical Documents Patents Terms and Conditions Trademarks
See all
Contact Product Support
See all
Overview
Collaborations and Alliances
See all
Contact Us Medical information request
See all
Overview
eLearning Successions Operator Training Live From Lakewood Technician Training Classes
See all
On-Demand Webinars and Videos Request education and training Request technician training
See all
Overview
Collaborations and Alliances Research and Grant Opportunities Patient Stories Sustainability Drop of Hope
See all
Executive Leadership Compliance Environment, Health, and Safety Policy Non-DEHP Commitment Terumo Integrity Hotline Ethylene Oxide and Sterilization in Healthcare
See all
Overview
Our Culture Our values are the heart of our culture Total Rewards Benefits, compensation, and other rewards Diversity and Belonging Committed to a work environment that welcomes differences and unique viewpoints
See all
Overview
Noteworthy Mentions Noteable news publications and mentions Insights Thought leadership articles News Releases Latest news and updates Media Resources Access media resources
See all
Terumo Global
Terumo Global
Global Blood Solutions

To maintain the highest level of blood safety while keeping costs down, our technologies and software can be implemented and integrated at each step along your supply chain from collection and processing to pathogen reduction and storage.

Learn more
Products
See all
Software & Services
See all
Therapeutic Apheresis

As a global leader in therapeutic apheresis and cell collections, Terumo Blood and Cell Technologies is dedicated to advancing apheresis to help provide more treatment options for the patients you serve.

Learn more
Products, Indications & Protocols
See all
Software & Services
See all
Cell Therapy Technologies

The field of cell therapy is a fast-moving, ever-changing landscape. We take pride in leading the way with comprehensive manufacturing strategies, customized solutions, and performance-focused products, all backed with the expertise and support to help guide your success.

Learn more
Products
See all
Software & Services
See all
Additional Products & Services

Additional offerings from Terumo Blood and Cell Technologies.

Learn more
Products
Software & Services
Product Support

View a variety of helpful links and resources related to our products, including access to the support portal

Learn more
Resources
Inquires
Contact Us

Get in touch with our product support team

Learn more
Work With Us
Inquiries
Training

Explore our variety of online and in-person learning opportunities

Learn more
Training & Classes
Resources
About Us

Read about how we are unlocking the potential of blood- and cell-based therapies, and explore additional resources about our company

Learn more
Our Impact
Our Commitment
Careers

Explore exciting global career opportunities at Terumo Blood and Cell Technologies

Learn more
Work With Us
News & Insights

Stay up-to-date with news, insights, and more

Learn more
News & Events
Location preference

Enter your country so we can show you products that are available for you.

  • Afghanistan   (AF)   |   English
  • Albania   (ALB)   |   English
  • Algeria   (DZ)   |   English
  • Argentina   (AR)   |   English
  • Armenia   (AM)   |   English
  • Australia   (AU)   |   English
  • Austria   (AT)   |   English
  • Azerbaijan   (AZ)   |   English
  • Bahamas   (BS)   |   English
  • Bahrain   (BH)   |   English
  • Bangladesh   (BD)   |   English
  • Barbados   (BB)   |   English
  • Belarus   (BY)   |   English
  • Belgium   (BE)   |   English
  • Belize   (BZ)   |   English
  • Benin   (BJ)   |   English
  • Benin   (GH)   |   English
  • Bhutan   (BT)   |   English
  • Bolivia   (BO)   |   English
  • Bosnia Herzegovina   (BA)   |   English
  • Brazil   (BR)   |   English
  • Brunei   (BN)   |   English
  • Bulgaria   (BG)   |    English
  • Cambodia   (KH)   |   English
  • Canada   (CA)   |   English
  • Chile   (CL)   |   English
  • China   (CN)   |   中文
  • Columbia   (COL)   |   English
  • Costa Rica   (CR)   |   English
  • Cote d'ivoire   (CI)   |   English
  • Croatia   (HR)   |   English
  • Cuba   (CU)   |   English
  • Cyprus   (CY)   |   English
  • Czech Republic   (CZ)   |   English
  • Denmark   (DK)   |   English
  • Dominican Republic   (DO)   |   English
  • Ecuador   (EC)   |   English
  • Egypt   (EG)   |   English
  • El Salvador   (SV)   |   English
  • Eritrea   (ERI)   |   English
  • Estonia   (EE)   |   English
  • Ethiopia   (ET)   |   English
  • Fiji   (FJ)   |   English
  • Finland   (FI)   |   English
  • France   (FR)   |   English
  • French Guiana   (GF)   |   English
  • Georgia   (GE)   |   English
  • Germany   (DE)   |   English
  • Global   |   English
  • Greece   (GR)   |   English
  • Guatemala   (GT)   |   English
  • Haiti   (HT)   |   English
  • Honduras   (HN)   |   English
  • Hong Kong SAR, China   (HK)   |    中国人
  • Hungary   (HU)   |   English
  • Iceland   (IS)   |   English
  • India   (IN)   |   English
  • Indonesia   (ID)   |   English
  • Iran   (IR)   |   English
  • Iraq   (IQ)   |   English
  • Ireland   (IE)   |   English
  • Israel   (IL)   |   English
  • Italy   (IT)   |   English
  • Jamaica   (JM)   |   English
  • Japan   (JP)   |   日本語
  • Jordan   (JO)   |   English
  • Kazakhstan   (KZ)   |   English
  • Kenya   (KE)   |   English
  • Kuwait   (KW)   |   English
  • Kyrgyzstan   (KG)   |   English
  • Laos   (LA)   |   English
  • Latvia   (LV)   |   English
  • Lebanon   (LB)   |   English
  • Liberia   (LR)   |   English
  • Libya   (LY)   |   English
  • Liechtenstein   (LI)   |   English
  • Lithuania   (LT)   |   English
  • Luxembourg   (LU)   |   English
  • Macedonia   (MK)   |   English
  • Malaysia   (MY)   |   English
  • Maldives   (MV)   |   English
  • Malta   (MT)   |   English
  • Mauritius   (MU)   |   English
  • Mexico   (MX)   |   English
  • Moldova   (MD)   |   English
  • Mongolia   (MN)   |   English
  • Montenegro   (ME)   |   English
  • Morocco   (MAR)   |   English
  • Mozambique   (MZ)   |   English
  • Myanmar   (MM)   |   English
  • Namibia   (NA)   |   English
  • Nepal   (NP)   |   English
  • Netherlands   (NL)   |   English
  • Netherlands Antilles   (AN)   |   English
  • New Caledonia   (NC)   |   English
  • New Zealand   (NZ)   |   English
  • Nicaragua   (NIC)   |   English
  • Nigeria   (NG)   |   English
  • Norway   (NO)   |   English
  • Oman   (OM)   |   English
  • Pakistan   (PK)   |   English
  • Palestine   (PS)   |   English
  • Panama   (PA)   |   English
  • Papua New Guinea   (PG)   |   English
  • Paraguay   (PY)   |   English
  • Peru   (PE)   |   English
  • Philippines   (PH)   |   English
  • Poland   (PL)   |   English
  • Portugal   (PT)   |   English
  • Puerto Rico   (PR)   |   English
  • Qatar   (QA)   |   English
  • Romania   (RO)   |   English
  • Russia   (RU)   |   English
  • Saudia Arabia   (SA)   |   English
  • Senegal   (SN)   |   English
  • Serbia   (RS)   |   English
  • Seychelles   (SC)   |   English
  • Singapore   (SG)   |   English
  • Slovakia   (SK)   |   English
  • Slovenia   (SI)   |   English
  • Solomon Islands   (SB)   |   English
  • South Africa   (ZA)   |   English
  • Spain   (ES)   |   English
  • Sri Lanka   (LK)   |   English
  • Sudan   (SD)   |   English
  • Sweden   (SE)   |   English
  • Switzerland   (CH)   |   English
  • Syria   (SY)   |   English
  • Taiwan, Province of China   (TW)   |    中国人
  • Tajikistan   (TJ)   |   English
  • Thailand   (TH)   |   English
  • Timor-Leste   (TL)   |   English
  • Togo   (TG)   |   English
  • Trinidad and Tobago   (TT)   |   English
  • Tunisia   (TN)   |   English
  • Turkey   (TR)   |   English
  • Turkmenistan   (TM)   |   English
  • Ukraine   (UA)   |   English
  • United Arab Emirates   (UAE)   |   English
  • United Kingdom   (GB)   |   English
  • United States   (US)   |   English
  • Uruguay   (UY)   |   English
  • Uzbekistan   (UZ)   |   English
  • Vietnam   (VN)   |   English
  • Yemen   (YE)   |   English
  • Zambia   (ZM)   |   English
Optia in use CMNC procedure operator changing target

Spectra Optia Cell Collection Services

Optimize your cell therapy starting material with insights based on 60 years of apheresis expertise

Drive improvement, gain insight, and increase control through your cell collection data

The best possible starting material is critical to providing the best outcome

Your cell therapy manufacturing process is highly dependent on the quality of your starting material. Whether you are just starting your CAR T-cell therapy clinical trial or scaling up from phase 1 to phase 2, the starting material collected from the patient matters. No two patients are the same, and collections can vary. Controlling what you can becomes all the more important.

Request information

Research of note

Variability in CAR T-cell expansion may be caused by the contamination of the starting peripheral blood mononuclear cell (PBMC) concentrates with monocytes (non-target cells).1 Read this journal article, originally published in Cytotherapy, for more information.

Plan your cell collection optimization roadmap

Let our expertise relating to apheresis, cell therapy starting material collection, and our Spectra Optia™ Apheresis System — paired with your Spectra Optia device procedural data — provide a roadmap for achieving your goals. Our services are designed to support:

  • Enhanced strategy
  • Data-driven decisions
  • Visibility into the process
  • Optimized starting product
  • Achievement of therapy objectives

Our cell collection-related services

Spectra Optia Cell Collection Data Analytics

  • Single or multiple procedure data analysis
  • Comprehensive analysis from pre-procedure data through final therapy results
  • Optimization recommendations
  • Collection site comparison and benchmarking 
  • On-site and off-site systems support

Spectra Optia Prediction Algorithm

  • Collection data review
  • Customized whole blood process calculation
  • Statistical summary analysis

Get more details about our cell collection services by visiting the Veda Solutions section of our website.

Learn more

Featured resources

For operator's manuals and Instructions for Use, visit our eIFU website: Terumo.eifu.com. For more information, visit Help.TerumoBCT.com.

Ready to have a conversation?

Contact us to speak with a Terumo Blood and Cell Technologies data analysis specialist.

Connect with our experts

Disclaimers and notes

  1. Stroncek DF, Ren J, Lee DW, et al. Cytotherapy. 2016;18(7):898-901. doi: 10.1016/j.jcyt.2016.04.003.
To top